Benitec Biopharma Inc (BNTC): Debts to Book Capitalization

Corporate company logo of Benitec (BNTC)

The market dynamics of Benitec Biopharma Inc. (BNTC) on the GURU.Markets platform rely on the stable specialized transport of biosamples supporting R&D, with the current indicator standing at 0.00. Business growth is driven by the success of the BB-301 drug and potential interest from industry behemoths. Meanwhile, robust patent protections and strict regulatory oversight create a high barrier to entry for competitors.

Benitec Biopharma Inc. (BNTC) - Debts to Book Value from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for Benitec Biopharma Inc (BNTC)

- price and consensus price forecast:
Stock Price Benitec Biopharma Inc.|BNTC - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Benitec Corp|BNTC - Total Company Value
- book capitalization data:
Book Value per Share Benitec Biopharma|BNTC - Total Stockholders' Equity|Market Value to Book Value Ratio benitec.com|BNTC - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Benitec Biopharma Inc.|BNTC - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Benitec|BNTC - Company Cumulative Indebtedness|Debts to Book Capitalization Benitec Corp
Fundamental company analysis:Benitec Biopharma Inc. - BNTC
Brand item of Benitec Corp

This indicator determines the ratio of total debt to equity, allowing for an assessment of financial leverage and default risk during fundamental analysis. By analyzing the shift in the proportion of total debt to book capitalization, an investor can understand how aggressively Benitec Biopharma Inc. (BNTC) finances its ddRNAi research and the acquisition of bioengineering patents through strategic alliances without overloading the balance sheet with liabilities.

Competitors of Benitec Biopharma Inc.

Debts to Book Capitalization TEM (Tempus AI Inc)|Debts to Book Capitalization qiagen.com QGEN|IONS - Debts to Book Capitalization|RGEN - Debt to Book Capitalization Ratio|Debts to Book Capitalization RNA|CRSP (CRISPR) - Debts to Book Value|Debt to Book Capitalization Ratio GeneDx Holdings Corp. (WGS)|Debt to Book Value Ratio ultragenyx.com|BEAM (Beam Therapeutics) - Debts to Book Capitalization|Debts to Net Assets Sarepta Therapeutics SRPT|Debt to Book Value Twist Bio (TWST)|Debt to Book Capital 10x TXG|NTLA (Intellia Therapeutics) - Debts to Book Capitalization|STOK - Debts to Book Value|BLFS (BioLife Solutions) - Debts to Book Capitalization|Debt to Book Value Wave Life Sciences Ltd|MAZE - Debt to Book Value|Debt to Net Assets Ratio Sionna Corp|Debts to Book Capitalization Prime Medicine, Inc. (PRME)|Debt to Book Capitalization Ratio tayshagtx.com (TSHA)|Debts to Book Capitalization QURE|MeiraGTx Holdings - Debts to Net Assets|RGNX (Regenxbio) - Debt to Book Capitalization Ratio|SLDB: Debts to Book Value|Debt to Book Capitalization Ratio Ocugen, Inc. (OCGN)|pacb.com (PACB) - Debts to Book Capitalization Ratio|DSGN - Debts to Book Capitalization|Debt to Net Assets Ratio Rocket Pharma|Debts to Book Capitalization FDMT|Debts to Book Capitalization LXEO (lexeotx.com)|Debt to Book Capitalization Ratio Korro Bio|editasmedicine.com - Debt to Net Assets Ratio|SLN: Debt to Book Capitalization Ratio|PRQR - Debt to Book Value|CDXS: Debts to Book Capitalization|Debts to Book Capitalization Sangamo BioSciences|NAUT - Debt to Book Value|Debt to Net Assets Ratio metagenomi.co|DTIL (Precision BioSciences, Inc.) - Debts to Book Capitalization|Debts to Net Assets GBIO (generationbio.com)|BOLD - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Exicure Inc. XCUR|IMNN: Debts to Book Capitalization|Phio Pharmaceuticals (PHIO) - Debt to Book Value|mustangbio.com - Debt to Book Value|TransCode Therapeutics, Inc. (RNAZ) - Debts to Net Assets|Debts to Book Capitalization Bionano Genomics Inc.|Debt to Book Capitalization Ratio APDN|Debt to Book Capitalization Ratio bluebird bio, Inc. BLUE|Debt to Book Value Ratio immunoprecise.com IPA|Debt to Book Value Omega Therapeutics, Inc. (OMGA)|Debt to Book Capital Singular Genomics Systems, Inc. OMIC|RGLS: Debts to Book Capitalization|SYRS - Debt to Book Value|Debts to Book Capitalization Telesis Bio, Inc.|TCON (traconpharma.com) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Unity Biotechnology, Inc. (UBX)